Jardiance Shows Cardiovascular Risk Reduction in Diabetic Patients
One of the leading healthcare company Eli Lilly & Co. and Germany based pharmaceutical company Boehringer Ingelheim just scored a coup. Their new diabetes medicine Jardiance in a clinical study has shown promising results that it can decrease the possibility of heart attack, stroke and death from cardiovascular reasons.
Diabetes can raise the possibility of cardiac disease and strokes, and so treating diabetes would also decrease the possibility of developing those issues. Earlier cardiovascular outcomes studies with diabetes drugs have not been successful in proving that.
According to Lilly and Boehringer Ingelheim
The new research, known as EMPA-REG OUTCOME, took a look at Jardiance’s outcomes in over 7,000 people with Type 2 diabetes who were at significant risk of heart attack or stroke. Including the Jardiance to the standard of care demonstrated that the combination did a superior job of reducing cardiovascular death, heart attack and stroke.
Hans-Juergen Woerle, Global Vice President of medicine at Boehringer Ingelheim said
The CV risk reduction effect shown by Jardiance in the EMPA-REG OUTCOME study is interesting and we look ahead to sharing the full outcomes. “Roughly half of deaths in individuals with Type 2 diabetes globally are triggered by cardiovascular disease. Decreasing cardiovascular risk is an important element of diabetes management.”
The new data give Jardiance a new gun for battling competitors in an significantly challenging diabetes market. Payers have become more aggressive in pitting diabetes medication against one another for formulary placement, reducing pricing freedom especially in drug classes with various competitors. In its category Jardiance takes on Johnson & Johnson’s Invokana and AstraZeneca’s Farxiga.
Additionally, there’s rivalry among drug classes, and the Jardiance results could make physicians more probably to prefer it over another non-insulin diabetes therapy. For example, a DPP-4 drug like Merck & Co.’s Januvia or a GLP-1 treatment like Novo Nordisk’s Victoza.